Therefore, we exploited the Treg-diluting potential of Lm-based vaccine to enhance the therapeutic efficacy of agonist anti-GITR Ab by combining these two treatments in TC-1 tumor-bearing mice. This evidence concerns the gene TNFRSF18 and neoplasm.